Wood, A. J. 2008. Playing “kick the FDA”—Risk-free to players but hazardous to public health. New England Journal of Medicine 358(17):1774–1775.
Yang, S. X., S. Kummar, S. M. Steinberg, A. J. Murgo, M. Gutierrez, L. Rubinstein, D. Nguyen, G. Kaur, A. P. Chen, V. L. Giranda, J. E. Tomaszewski, J. H. Doroshow, and The National Cancer Institute Phase 0 Working Group. 2009. Immunohistochemical detection of poly(ADP-ribose)polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biology and Therapy 8(21)2004–2009.
Yetley, E. A. 2007. Science in the regulatory setting: A challenging but incompatible mix? Novartis Foundation Symposium 282:59–68; discussion 69–76, 212–218.
Zarin, D. A., N. C. Ide, T. Tse, W. R. Harlan, J. C. West, and D. A. Lindberg. 2007. Issues in the registration of clinical trials. Journal of the American Medical Association 297(19):2112– 2120.